{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:21:20Z","timestamp":1787800880376,"version":"build-2784847793"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,4,28]],"date-time":"2015-04-28T00:00:00Z","timestamp":1430179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Patients with mantle cell lymphoma (<jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>) generally respond to first\u2010line immunochemotherapy, but often show chemoresistance upon subsequent relapses, with poor outcome. Several studies of the immunomodulator, lenalidomide, have demonstrated its activity in <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> including the <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\u2010001 study in relapsed\/refractory patients who had failed defined prior therapies of anthracyclines or mitoxantrone, cyclophosphamide, rituximab and also bortezomib. We present here the long\u2010term efficacy follow\u2010up of the prospective phase <jats:styled-content style=\"fixed-case\">II MCL<\/jats:styled-content>\u2010001 study (<jats:italic>N<\/jats:italic>\u00a0=\u00a0134), including new exploratory analyses with baseline Ki\u201067 (<jats:styled-content style=\"fixed-case\">MIB<\/jats:styled-content>1), a biological marker of tumour proliferation. With longer follow\u2010up, lenalidomide showed a 28% overall response rate [<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>; 8% complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>)\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> unconfirmed (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>u)]. Median duration of response (<jats:styled-content style=\"fixed-case\">DOR<\/jats:styled-content>), progression\u2010free survival and overall survival were 16\u00b76, 4\u00b70 and 20\u00b79\u00a0months, respectively. Myelosuppression continued to be the most common grade 3\/4 toxicity. Several studies of <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> patients treated with chemotherapy, rituximab and bortezomib have shown an inverse association between survival and Ki\u201067. Ki\u201067 data in 81\/134 <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\u2010001 patients showed similar <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>s in both low (&lt;30% or &lt;50%) <jats:italic>versus<\/jats:italic> high (\u226530% or \u226550%) Ki\u201067\u2013expressing groups, yet lower Ki\u201067 levels demonstrated superior <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>u, <jats:styled-content style=\"fixed-case\">DOR<\/jats:styled-content> and survival outcomes. Overall, lenalidomide showed durable efficacy with a consistent safety profile in heavily pretreated, relapsed\/refractory <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content> post\u2010bortezomib.<\/jats:p>","DOI":"10.1111\/bjh.13456","type":"journal-article","created":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T03:08:19Z","timestamp":1430276899000},"page":"496-503","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Longer\u2010term follow\u2010up and outcome by tumour cell proliferation rate (Ki\u201067) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL\u2010001(EMERGE) pivotal trial"],"prefix":"10.1111","volume":"170","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[{"name":"John Theurer Cancer Center at HUMC Hackensack NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Kalayoglu Besisik","sequence":"additional","affiliation":[{"name":"Istanbul University Faculty of Medicine Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[{"name":"Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Indiana University Medical Center Indianapolis IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irit","family":"Avivi","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Shaare Zedek Medical Centre Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Herbrecht","sequence":"additional","affiliation":[{"name":"H\u00f4pital de Hautepierre Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achiel","family":"Van Hoof","sequence":"additional","affiliation":[{"name":"General Hospital St\u2010Jan Brugge Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Cicero","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Fu","sequence":"additional","affiliation":[{"name":"Celgene Corporation Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Witzig","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester MN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.09.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.483302"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0871"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12046"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.09.027"},{"key":"e_1_2_8_14_1","article-title":"Combination biologic therapy without chemotherapy as initial treatment for mantle cell lymphoma: multi\u2010center phase II study of lenalidomide plus rituximab","volume":"122","author":"Ruan J.","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.815349"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0358"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23176"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4405"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21468"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt366"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13456","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13456","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.13456","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T16:13:33Z","timestamp":1696349613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,28]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1111\/bjh.13456"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13456","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,28]]},"assertion":[{"value":"2014-12-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}